Atom Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Lingdolinurad (ABP-671) for Chronic Kidney Disease with Hyperuricemia

Posted on by sHq_LoGiNz

HANGZHOU, China & NEWARK, Calif.–(BUSINESS WIRE)–First Patient Dosed in Atom’s Phase 2 Clinical Trial of Lingdolinurad (ABP-671) for Chronic Kidney Disease with Hyperuricemia

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance (opens in a new tab)
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.